MyHealthChecked PLC Launch of COVID-19 rapid antigen test service (3344T)
24 Noviembre 2021 - 12:59AM
UK Regulatory
TIDMMHC
RNS Number : 3344T
MyHealthChecked PLC
24 November 2021
MyHealthChecked PLC
("MyHealthChecked" or the "Company")
Launch of COVID-19 Day 2 rapid antigen test and verification
service
MyHealthChecked Plc (AIM: MHC), announces the launch of two home
testing services for travellers entering and departing the UK. On
24 November the company will begin selling a rapid antigen test and
a verification service for residents and vaccinated travellers
arriving in England from a non-red list country, followed by a Fit
to Fly rapid test for travellers leaving the UK launching next
week.
The online service will allow customers to order a test before
arriving into England (where COVID-19 travel rules are different to
those in Scotland, Wales and Northern Ireland) or departing from
the UK. The test can be taken at home with results verified by a
trained professional within 2 hours of completing the test.
Customers are then notified by email when the result is ready, and
a QR-code secured COVID-19 result certificate is made available for
download.
The service will utilise the CE approved, ISO certified and UK
Government validated FlowFlex(R) Rapid Test Kit, a lateral flow
test that is easy to administer via a simple nasal swab, which
provides results in 15 minutes and offers 98.8% accuracy.
MyHealthChecked has also partnered with medical specialists
Mediskills, who will provide fully trained NHS professionals to
verify test results as part of this service. MyHealthChecked will
have full responsibility for overseeing the service, processing
orders and dispatches, as well as warehousing test kit stock. The
Company will continue to maintain the high standards of customer
service already being delivered across its other testing
services.
MyHealthChecked remains a high-quality laboratory provider but
has adapted to evolving market requirements, allowing the Company's
reputation for delivering a good customer experience and a reliable
testing service across a wider variety of testing formats.
Penny McCormick, Chief Executive Officer of MyHealthChecked PLC
, commented: "I am delighted to announce the launch our new
COVID-19 Day 2 rapid antigen testing service. Our agility in
adapting to the changing market needs shows the strength of our
team, our digital platform, and our ability to offer customers
highly compliant testing services via on a digital platform that
gives a great user experience. Our focus on ensuring the best
possible customer service has already allowed us to meet the needs
of our key retail partners and has established a trusted
relationship based on the best possible service delivery."
MyHealthChecked PLC www.myhealthchecked.com
P enny McCormick , Chief Executive via Walbrook PR
Officer
Gareth Davies, Chief Financial and
Operations Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Oberon Capital Ltd (Broker) Tel: +44 (0)203 179 5344
Mike Seabrook mikeseabrook@oberoninvestments.com
Walbrook PR Ltd (Media & Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
IR)
Paul McManus / Alice Woodings Mob: +44(0)7980 541 893 / +44 (0)7407
804 654
About MyHealthChecked PLC ( www.myhealthcheckedplc.com )
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted
pioneering UK healthcare company focused on a range of at-home
healthcare and wellness tests. MyHealthChecked is the umbrella
brand of a range of at-home DNA and RNA tests, now in development
following the acquisition of The Genome Store in November 2020. The
tests will be made available online and would be viable for
over-the-counter purchase.
The MyHealthChecked portfolio has been identified as part of a
change in mindset as customers become more familiar with the
concept of accessible healthcare in the growing at home testing kit
market, with a focus on accessibility at the right price, led by
UK-based experts.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFLTLILVFIL
(END) Dow Jones Newswires
November 24, 2021 01:59 ET (06:59 GMT)
Concepta (LSE:CPT)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Concepta (LSE:CPT)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024